At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany.

OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs. It strives to fulfill its mission of supplying everything a researcher needs for gene-based research. Through licensing and selling research materials including genes, proteins, and research tools, it enables critical biological research.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Nanjing Safe Biotechnology Co., Ltd., established on 2013-10-22, The business scope includes feed additives,cosmetic,Chemical Products(except dangerous goods)technology research and development,Technical Consulting and Technical Services;cosmetic,Chemical Products(except dangerous goods)Wholesale.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Therion Biologics Corporation is focusing on the development and commercialization of innovative vaccines for the treatment of major cancers. Currently, Therion has two lead products moving into pivotal clinical trials in the next two years: PROSTVAC-VF for prostate cancer, developed by Therion, and ALVAC-CEA/B7.1, developed in collaboration with Aventis Pasteur Ltd., for colorectal cancer. The company also has a broad pipeline of vaccines in early clinical development for treatment of other major cancers, including breast cancer, lung cancer, melanoma and other solid tumors. Therion's partners include Aventis Pasteur, the National Cancer Institute and a network of leading clinical institutions around the world. Therion is a privately-held biotechnology company headquartered in Cambridge, Massachusetts. Therion's goal is to generate safe and effective therapeutic cancer vaccines that stimulate the immune system to specifically attack cancer cells, and thereby stabilize disease or induce tumor regression, improve patients' quality of life, and increase patient survival. While there has been significant progress in the treatment of some cancers, the prognosis for many cancer patients remains poor. For example, colorectal cancer affects an estimated 130,000 new patients and accounts for 56,300 deaths each year in the United States. Prostate cancer is the second leading cause of cancer death in men, with an estimated 180,400 new cases and 31,900 deaths in the U.S. annually. Recent advances in immunology and tumor biology have opened the door for the development of new generation therapeutic cancer vaccines. In particular, scientists now have a better understanding of the key molecular signals involved in eliciting potent and specific immune responses. This allows researchers to engineer vaccines that induce elements of the immune system required to eliminate cancer cells. Therion is at the forefront, quickly moving leading research into clinical development. Capitalizing on these recent scientific advances, Therion is targeting many of the major cancers currently lacking adequate treatment. Therion's therapeutic cancer vaccines for breast, lung, colorectal and prostate cancers, and melanoma address a majority of the large and rapidly growing market for cancer treatments.

Korea Hydro & Nuclear Power Co. Ltd. produces and supplies electric power. It operates nuclear plants in Busan, Ulsan, North-Gyeongsang, and North-Jeonla and renewable energy generation facilities. The company was founded on April 2, 2001 and is headquartered in Seoul, South Korea.

Based in Cologne, Germany, Sividon Diagnostics is a management buyout from Siemens Healthcare Diagnostics in Cologne. The aim of Sividon team of experienced scientists and managers was and still is, the quality of companion diagnostics in oncology to improve their products sustainably. So in the future treatment decisions could in cancer - especially breast cancer - will be further improved by an individualized, evidence-based diagnosis. In this way Sividon is also supported by an established international network of renowned experts. In addition to the many years of professional experience in molecular diagnostics, there are the extensive rights and to the year 2004 reaching back arrangements that characterize the team and Sividon.

Shanghai Ruoke Biotechnology Co., Ltd., established on 2011-12-01, Business scope includes licensed projects:Class III medical device business;Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services,Sales of Class I Medical Devices;Sales of Class II Medical Devices;Experimental analysis instrument sales;Research and development of intelligent robots;R&D and application of cell technology;Mechanical equipment research and development;Manufacturing of experimental analysis instruments.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX.

Huayin Health is a comprehensive healthcare and medical service group, focuses on providing laboratory and pathological services.

Tianjin Medical University General Hospital (Chinese: 天津医科大学总医院) is a general hospital in the central Heping District of the Chinese metropolis of Tianjin, associated with Tianjin Medical University.

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.